Details of the Drug Combination

General Information of Drug Combination (ID: DC8FZV4)

Drug Combination Name
Ruxolitinib Ifosfamide
Indication
Disease Entry Status REF
Large cell lung carcinoma Investigative [1]
Component Drugs Ruxolitinib   DM7Q98D Ifosfamide   DMCT3I8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: NCI-H460
Zero Interaction Potency (ZIP) Score: 3.47
Bliss Independence Score: 9.35
Loewe Additivity Score: 7.49
LHighest Single Agent (HSA) Score: 8.06

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ruxolitinib
Disease Entry ICD 11 Status REF
Essential thrombocythemia 3B63.1Z Approved [2]
High-risk myelofibrosis 2A20.2 Approved [3]
Myelofibrosis 2A22 Approved [4]
Myeloproliferative neoplasm 2A20 Approved [5]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Pancreatic cancer 2C10 Phase 3 [3]
Atopic dermatitis EA80 Phase 1/2 [7]
Vitiligo ED63.0 Phase 1/2 [7]
Ruxolitinib Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Modulator [10]
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [10]
Urokinase plasminogen activator surface receptor (PLAUR) TTPRL03 UPAR_HUMAN Inhibitor [11]
HUMAN janus kinase 1 (JAK-1) TTWKB01 JAK1_HUMAN Inhibitor [12]
HUMAN janus kinase 2 (JAK-2) TT0F5HE JAK2_HUMAN Inhibitor [12]
------------------------------------------------------------------------------------
Ruxolitinib Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Increases ADR [13]
------------------------------------------------------------------------------------
Indication(s) of Ifosfamide
Disease Entry ICD 11 Status REF
Adult central nervous system germ cell tumor N.A. Approved [8]
Adult teratoma N.A. Approved [8]
Advanced cancer 2A00-2F9Z Approved [8]
Extragonadal germ cell cancer N.A. Approved [8]
Extragonadal germ cell tumor N.A. Approved [8]
Kidney neoplasm N.A. Approved [8]
Solid tumour/cancer 2A00-2F9Z Approved [9]
Testicular germ cell tumor N.A. Approved [8]
Extragonadal nonseminomatous germ cell tumor N.A. Investigative [8]
Extragonadal seminoma N.A. Investigative [8]
Neuroblastoma 2D11.2 Investigative [8]
Retinoblastoma 2D02.2 Investigative [8]
Ifosfamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [15]
------------------------------------------------------------------------------------
Ifosfamide Interacts with 10 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [16]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [18]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [19]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Metabolism [20]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [18]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [21]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [22]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [20]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DME(s)
Ifosfamide Interacts with 214 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Activity [23]
Cytochrome P450 2C18 (CYP2C18) OTY687L9 CP2CI_HUMAN Increases Activity [23]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Ethylation [24]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Ethylation [24]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Affects Hydroxylation [17]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Increases Response To Substance [25]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Response To Substance [25]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Response To Substance [26]
Beta-2-microglobulin (B2M) OTDWN6NX B2MG_HUMAN Increases Expression [27]
Alpha-2A adrenergic receptor (ADRA2A) OTZFGOTP ADA2A_HUMAN Increases ADR [13]
Interleukin-19 (IL19) OT9VGDIP IL19_HUMAN Increases Secretion [28]
Solute carrier family 12 member 8 (SLC12A8) OTHJP5FU S12A8_HUMAN Decreases Expression [14]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [14]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Increases Expression [14]
Podocalyxin (PODXL) OTPNQXF3 PODXL_HUMAN Decreases Expression [14]
Class E basic helix-loop-helix protein 40 (BHLHE40) OTITX14U BHE40_HUMAN Increases Expression [14]
TRAF-type zinc finger domain-containing protein 1 (TRAFD1) OT7AU2R3 TRAD1_HUMAN Increases Expression [14]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [14]
Rho guanine nucleotide exchange factor 10 (ARHGEF10) OTHJ1Y4I ARHGA_HUMAN Affects Expression [14]
Protein phosphatase 1D (PPM1D) OT8NLZ9D PPM1D_HUMAN Decreases Expression [14]
Apoptosis regulatory protein Siva (SIVA1) OTDT0XZK SIVA_HUMAN Increases Expression [14]
Transcription factor MafG (MAFG) OTBQFUZH MAFG_HUMAN Increases Expression [14]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Increases Expression [14]
E3 ubiquitin-protein ligase SIAH2 (SIAH2) OTKED2XN SIAH2_HUMAN Increases Expression [14]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Increases Expression [14]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Increases Expression [14]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) OTLVN68B AAKB2_HUMAN Affects Expression [14]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20) OT6CLFXB MCAT_HUMAN Increases Expression [14]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Decreases Expression [14]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A) OT4RF9Z4 PDE8A_HUMAN Decreases Expression [14]
Mitochondrial import inner membrane translocase subunit Tim17-B (TIMM17B) OTSQGLSB TI17B_HUMAN Decreases Expression [14]
PR domain zinc finger protein 1 (PRDM1) OTQLSVBS PRDM1_HUMAN Decreases Expression [14]
E3 ubiquitin-protein ligase listerin (LTN1) OTIW2HTX LTN1_HUMAN Decreases Expression [14]
Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) OT1G9297 TFIP8_HUMAN Increases Expression [14]
Tetraspanin-12 (TSPAN12) OTF9I3CX TSN12_HUMAN Decreases Expression [14]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Increases Expression [14]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases Expression [14]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Increases Expression [14]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Increases Expression [14]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [14]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [14]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [14]
Fatty acid-binding protein, heart (FABP3) OT562DA1 FABPH_HUMAN Decreases Expression [14]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Decreases Expression [14]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Affects Expression [14]
Glycogen phosphorylase, liver form (PYGL) OTS1YFGR PYGL_HUMAN Decreases Expression [14]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [14]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [14]
Keratin, type I cytoskeletal 19 (KRT19) OTDGDQ75 K1C19_HUMAN Increases Expression [14]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Increases Expression [14]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [14]
RNA-binding protein RO60 (RO60) OTLGM5A8 RO60_HUMAN Decreases Expression [14]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Increases Expression [14]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases Expression [14]
Cation-independent mannose-6-phosphate receptor (IGF2R) OTDXPQVX MPRI_HUMAN Increases Expression [14]
Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) OTV04QE5 P4HA1_HUMAN Decreases Expression [14]
Fos-related antigen 1 (FOSL1) OT9YTYMB FOSL1_HUMAN Increases Expression [14]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Decreases Expression [14]
Protein SON (SON) OT9VWV18 SON_HUMAN Decreases Expression [14]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Affects Activity [14]
Keratin, type I cytoskeletal 15 (KRT15) OTS6WLF7 K1C15_HUMAN Increases Expression [14]
Ephrin-A1 (EFNA1) OTU2NUA2 EFNA1_HUMAN Decreases Expression [14]
Iduronate 2-sulfatase (IDS) OTZO94EO IDS_HUMAN Decreases Expression [14]
Ferrochelatase, mitochondrial (FECH) OTDWEI6C HEMH_HUMAN Decreases Expression [14]
Diacylglycerol kinase alpha (DGKA) OTTBVNEZ DGKA_HUMAN Increases Expression [14]
Thromboxane-A synthase (TBXAS1) OTAXZJJ4 THAS_HUMAN Increases Expression [14]
Bromodomain-containing protein 2 (BRD2) OTQP2MVJ BRD2_HUMAN Decreases Expression [14]
DnaJ homolog subfamily B member 2 (DNAJB2) OTZHPV5M DNJB2_HUMAN Increases Expression [14]
Neuropeptide Y receptor type 1 (NPY1R) OT5DA9DY NPY1R_HUMAN Increases Expression [14]
Threonine--tRNA ligase 1, cytoplasmic (TARS1) OT0PWST5 SYTC_HUMAN Decreases Expression [14]
Adenylate kinase 4, mitochondrial (AK4) OTA0T02Q KAD4_HUMAN Increases Expression [14]
ETS domain-containing protein Elk-4 (ELK4) OTVSSEOE ELK4_HUMAN Decreases Expression [14]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [14]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [14]
Pyrroline-5-carboxylate reductase 1, mitochondrial (PYCR1) OTQHB52T P5CR1_HUMAN Increases Expression [14]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Affects Expression [14]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Decreases Expression [14]
Thrombospondin-2 (THBS2) OTXET551 TSP2_HUMAN Decreases Expression [14]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [14]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Affects Activity [14]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Affects Activity [14]
Transaldolase (TALDO1) OTDKV2S2 TALDO_HUMAN Increases Expression [14]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [14]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [14]
Isoleucine--tRNA ligase, cytoplasmic (IARS1) OT9WXH5N SYIC_HUMAN Increases Expression [14]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [14]
Eukaryotic translation initiation factor 1 (EIF1) OTB4GZ0V EIF1_HUMAN Increases Expression [14]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Decreases Expression [14]
Retinaldehyde dehydrogenase 3 (ALDH1A3) OT1C9NKQ AL1A3_HUMAN Increases Expression [14]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9) OTHRUON2 SC6A9_HUMAN Decreases Expression [14]
NADP-dependent malic enzyme (ME1) OTSVEUQE MAOX_HUMAN Decreases Expression [14]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Decreases Expression [14]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Increases Expression [14]
Cysteine--tRNA ligase, cytoplasmic (CARS1) OTOUZF6O SYCC_HUMAN Decreases Expression [14]
Serine--tRNA ligase, cytoplasmic (SARS1) OTFKXQ1O SYSC_HUMAN Increases Expression [14]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Decreases Expression [14]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Expression [14]
Dipeptidyl peptidase 1 (CTSC) OT79WJZZ CATC_HUMAN Increases Expression [14]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [14]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [14]
Homeobox protein DLX-1 (DLX1) OT7BH057 DLX1_HUMAN Decreases Expression [14]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Increases Expression [14]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Affects Expression [14]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [14]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [14]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [14]
Transmembrane protein 94 (TMEM94) OTT4ZSUA TMM94_HUMAN Decreases Expression [14]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Decreases Expression [14]
Zinc finger protein Rlf (RLF) OTCSPZVK RLF_HUMAN Increases Expression [14]
Peptidyl-prolyl cis-trans isomerase G (PPIG) OTZ8BTTM PPIG_HUMAN Decreases Expression [14]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [14]
Ras-related protein Rab-31 (RAB31) OTMLXQZ0 RAB31_HUMAN Increases Expression [14]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Expression [14]
Src substrate cortactin (CTTN) OTJRG4ES SRC8_HUMAN Increases Expression [14]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Decreases Expression [14]
Protein disulfide-isomerase A5 (PDIA5) OT76ZSX5 PDIA5_HUMAN Increases Expression [14]
Condensin complex subunit 1 (NCAPD2) OT8VGE2O CND1_HUMAN Increases Expression [14]
Probable E3 ubiquitin-protein ligase HERC3 (HERC3) OTWMKYD9 HERC3_HUMAN Decreases Expression [14]
kinase isozyme 1, mitochondrial (PDK1) OTMABK9Z PDK1_HUMAN Decreases Expression [14]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Increases Expression [14]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Affects Activity [14]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [14]
Neuronal regeneration-related protein (NREP) OT2AZPKK NREP_HUMAN Affects Expression [14]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Affects Activity [14]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Expression [14]
Laminin subunit alpha-3 (LAMA3) OTFME7HT LAMA3_HUMAN Increases Expression [14]
Atos homolog protein A (ATOSA) OTWFM5G0 ATOSA_HUMAN Decreases Expression [14]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Increases Expression [14]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [14]
RRP12-like protein (RRP12) OTQQAEH4 RRP12_HUMAN Increases Expression [14]
ALS2 C-terminal-like protein (ALS2CL) OT8RY7TZ AL2CL_HUMAN Affects Expression [14]
Dynamin-binding protein (DNMBP) OTMHH14H DNMBP_HUMAN Increases Expression [14]
Ribosomal protein eS27-like (RPS27L) OTZWHU0N RS27L_HUMAN Increases Expression [14]
Arginine/serine-rich coiled-coil protein 2 (RSRC2) OTLE0KQM RSRC2_HUMAN Decreases Expression [14]
Mitochondrial enolase superfamily member 1 (ENOSF1) OT65D3ZK ENOF1_HUMAN Decreases Expression [14]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Decreases Expression [14]
Protein LYRIC (MTDH) OTGH7N4C LYRIC_HUMAN Decreases Expression [14]
Liprin-beta-1 (PPFIBP1) OTRA2S7B LIPB1_HUMAN Increases Expression [14]
Dynein axonemal intermediate chain 3 (DNAI3) OTG1A0QP DNAI3_HUMAN Decreases Expression [14]
Extracellular sulfatase Sulf-2 (SULF2) OTIXMUVL SULF2_HUMAN Decreases Expression [14]
Protein O-mannosyl-transferase TMTC2 (TMTC2) OTY1QWYU TMTC2_HUMAN Decreases Expression [14]
Ninein (NIN) OTVH3M4Z NIN_HUMAN Decreases Expression [14]
Ceramide synthase 5 (CERS5) OT5A2DNI CERS5_HUMAN Increases Expression [14]
Uncharacterized protein C8orf58 (C8ORF58) OTHW01L0 CH058_HUMAN Increases Expression [14]
F-box only protein 22 (FBXO22) OTEJ5MO0 FBX22_HUMAN Increases Expression [14]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Increases Expression [14]
F-box only protein 30 (FBXO30) OTD1P6LA FBX30_HUMAN Decreases Expression [14]
Pantothenate kinase 1 (PANK1) OT2CZVRT PANK1_HUMAN Decreases Expression [14]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1) OT0HYZIU S3TC1_HUMAN Decreases Expression [14]
Uncharacterized protein C4orf3 (C4ORF3) OT6TFN1O CD003_HUMAN Decreases Expression [14]
Paraspeckle component 1 (PSPC1) OTYS6WQ8 PSPC1_HUMAN Decreases Expression [14]
Histone acetyltransferase KAT6B (KAT6B) OTMUDTAH KAT6B_HUMAN Decreases Expression [14]
E3 ubiquitin-protein ligase rififylin (RFFL) OT85MGDH RFFL_HUMAN Increases Expression [14]
Probable ATP-dependent RNA helicase DDX17 (DDX17) OTXRMMBP DDX17_HUMAN Decreases Expression [14]
GTP-binding protein Rit1 (RIT1) OTVNOGOH RIT1_HUMAN Increases Expression [14]
KICSTOR complex protein ITFG2 (ITFG2) OT0NLZ8I ITFG2_HUMAN Decreases Expression [14]
Protein TMEPAI (PMEPA1) OTY8Z9UF PMEPA_HUMAN Increases Expression [14]
Protein FAM162A (FAM162A) OT882DND F162A_HUMAN Decreases Expression [14]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [14]
SPRY domain-containing SOCS box protein 1 (SPSB1) OTGY26U4 SPSB1_HUMAN Increases Expression [14]
Carboxymethylenebutenolidase homolog (CMBL) OT8H3S3G CMBL_HUMAN Increases Expression [14]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Increases Expression [14]
Protein FAM89A (FAM89A) OTNASAXT FA89A_HUMAN Increases Expression [14]
ERO1-like protein alpha (ERO1A) OTVKOQWM ERO1A_HUMAN Increases Expression [14]
Protein FAM210B, mitochondrial (FAM210B) OT2QHEQ6 F210B_HUMAN Decreases Expression [14]
E1A-binding protein p400 (EP400) OTVQ75NX EP400_HUMAN Decreases Expression [14]
Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) OT9C3KFI KKCC2_HUMAN Increases Expression [14]
ETS-related transcription factor Elf-4 (ELF4) OT167PR5 ELF4_HUMAN Increases Expression [14]
Eukaryotic translation initiation factor 3 subunit C (EIF3C) OTR8RF9X EIF3C_HUMAN Decreases Expression [14]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [14]
Cancer-related nucleoside-triphosphatase (NTPCR) OTTRT6Z9 NTPCR_HUMAN Increases Expression [14]
G-protein coupled receptor 87 (GPR87) OTQX45UM GPR87_HUMAN Decreases Expression [14]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [14]
G protein-coupled receptor 88 (GPR88) OTGAT70V GPR88_HUMAN Increases Expression [14]
Coiled-coil domain-containing protein 90B, mitochondrial (CCDC90B) OTFFWB0C CC90B_HUMAN Decreases Expression [14]
Polyprenol reductase (SRD5A3) OT9IJLX7 PORED_HUMAN Decreases Expression [14]
E3 ubiquitin ligase RNF121 (RNF121) OTA0YMLW RN121_HUMAN Decreases Expression [14]
Ankyrin repeat family A protein 2 (ANKRA2) OTLSLV5A ANRA2_HUMAN Decreases Expression [14]
p53-induced death domain-containing protein 1 (PIDD1) OTWFM930 PIDD1_HUMAN Decreases Expression [14]
ATP-binding cassette sub-family B member 6 (ABCB6) OTPGZFES ABCB6_HUMAN Increases Expression [14]
ABC-type oligopeptide transporter ABCB9 (ABCB9) OTSOBOL5 ABCB9_HUMAN Increases Expression [14]
Fructose-2,6-bisphosphatase TIGAR (TIGAR) OTR7NMRJ TIGAR_HUMAN Increases Expression [14]
Dual specificity protein phosphatase 22 (DUSP22) OTEZ3U85 DUS22_HUMAN Increases Expression [14]
PAK4-inhibitor INKA2 (INKA2) OT9RA64U INKA2_HUMAN Increases Expression [14]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [14]
LIM and cysteine-rich domains protein 1 (LMCD1) OT3AWE8O LMCD1_HUMAN Decreases Expression [14]
Signal-induced proliferation-associated 1-like protein 2 (SIPA1L2) OT8NJE5D SI1L2_HUMAN Decreases Expression [14]
Dolichol-phosphate mannosyltransferase subunit 3 (DPM3) OTSB4XO0 DPM3_HUMAN Increases Expression [14]
DnaJ homolog subfamily B member 9 (DNAJB9) OT38EQT6 DNJB9_HUMAN Increases Expression [14]
Mitochondrial fission process protein 1 (MTFP1) OT3L6F7U MTFP1_HUMAN Increases Expression [14]
SERTA domain-containing protein 1 (SERTAD1) OTBHKZQP SRTD1_HUMAN Increases Expression [14]
Oxidative stress-induced growth inhibitor 1 (OSGIN1) OT9KIVZW OSGI1_HUMAN Decreases Expression [14]
Heme transporter FLVCR2 (FLVCR2) OTAM94ID FLVC2_HUMAN Decreases Expression [14]
Exocyst complex component 7 (EXOC7) OT4YA137 EXOC7_HUMAN Increases Expression [14]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Affects Expression [14]
Lysine-specific demethylase 3A (KDM3A) OTZYJ8VN KDM3A_HUMAN Decreases Expression [14]
RNA polymerase II subunit A C-terminal domain phosphatase (CTDP1) OTHHFW17 CTDP1_HUMAN Decreases Expression [14]
Pleckstrin homology-like domain family A member 3 (PHLDA3) OTXFUDO2 PHLA3_HUMAN Increases Expression [14]
Insulin-induced gene 2 protein (INSIG2) OTX4VY51 INSI2_HUMAN Increases Expression [14]
Phosphoserine aminotransferase (PSAT1) OTVV1YV9 SERC_HUMAN Increases Expression [14]
Sestrin-1 (SESN1) OTSFDZWL SESN1_HUMAN Increases Expression [14]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [29]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [30]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Decreases Expression [31]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Affects Expression [30]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [29]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [30]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Decreases Activity [32]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [30]
Elastin (ELN) OTFSO7PG ELN_HUMAN Increases ADR [13]
S-adenosylmethionine decarboxylase proenzyme (AMD1) OTKAGZY3 DCAM_HUMAN Increases ADR [13]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [33]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Increases ADR [13]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Response To Substance [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 214 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Clear cell renal cell carcinoma DCVOMA8 786-0 Investigative [34]
Glioma DC2080A SF-268 Investigative [34]
Plasma cell myeloma DCOWOMQ RPMI-8226 Investigative [34]
Invasive ductal carcinoma DCZ4OHV HS 578T Investigative [35]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Ruxolitinib FDA Label
6 Incyte begins Phase III trial of ruxolitinib to treat Covid-19. 20.April.2020.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Ifosfamide FDA Label
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
10 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
11 Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
12 The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
13 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
14 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
15 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
16 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
17 Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
18 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
19 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
20 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
21 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
22 A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
23 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
24 Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
25 Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome p450 isoforms for genotoxicity examination. Toxicol Sci. 2010 Aug;116(2):488-97. doi: 10.1093/toxsci/kfq154. Epub 2010 May 27.
26 Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998 Oct 1;58(19):4391-401.
27 A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer. 1995 Dec 15;76(12):2557-64. doi: 10.1002/1097-0142(19951215)76:12<2557::aid-cncr2820761223>3.0.co;2-9.
28 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
29 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
30 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
31 Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide. In Vivo. 1992 Mar-Apr;6(2):219-21.
32 Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol Genet Metab. 1998 Nov;65(3):238-45. doi: 10.1006/mgme.1998.2760.
33 Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. J Pediatr Hematol Oncol. 2005 Nov;27(11):582-9. doi: 10.1097/01.mph.0000187429.52616.8a.
34 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
35 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.